Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | WP1066 |
| Synonyms | |
| Therapy Description |
WP1066 is an inhibitor of JAK2, JAK2 V617F, and STAT3, which inhibits cell proliferation (PMID: 18245540, PMID: 21792892). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| WP1066 | JAK2 Inhibitor 19 STAT3 Inhibitor 26 | WP1066 is an inhibitor of JAK2, JAK2 V617F, and STAT3, which inhibits cell proliferation (PMID: 18245540, PMID: 21792892). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04334863 | Phase I | WP1066 | AflacST1901: Peds WP1066 | Completed | USA | 0 |
| NCT01904123 | Phase I | WP1066 | A Phase I Trial of WP1066 | Completed | USA | 0 |
| NCT05879250 | Phase II | WP1066 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |